Clinical Trial Update: Efficacy Assessment of the Cell Therapy Medicine NC1 in Patients With Post-traumatic Syringomyelia [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing the efficacy of the cell therapy medicine NC1 in patients with post-traumatic syringomyelia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Syringomyelia

Drugs mentioned

• NC1

Snippet

Sponsor: Puerta de Hierro University Hospital | Conditions: Post-Traumatic Syringomyelia | Phase 2 | Status: COMPLETED